Attention Deficit Hyperactivity Disorder (ADHD)
Conditions
Brief summary
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard ADHD treatment. Approximately 297 subjects aged 6 to 12 years with ADHD and comorbid impulsive aggression will be recruited in this study. The frequency of impulsive aggression behaviors will be assessed as a primary outcome. Additionally, the severity and improvement in impulsive aggression and quality of life measures for the subject and caregiver will be assessed using validated scales.
Detailed description
This study is a randomized, placebo-controlled, double-blind, multicenter, parallel group, fixed dose study to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of IA in subjects aged 6 to 12 years with ADHD in conjunction with standard ADHD treatment.
Interventions
DRUGSPN-810 (18 mg)
Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
DRUGSPN-810 (36 mg)
Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
DRUGPlacebo
Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Sponsors
Supernus Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* Otherwise healthy male or female subjects, age 6 to 12 years at the time of screening with a primary diagnosis of ADHD and currently receiving monotherapy treatment with an optimized FDA-approved ADHD medication. * Impulsive aggression will be confirmed at screening using R-MOAS and Vitiello Aggression Scale.
Exclusion criteria
* Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar disorder, schizophrenia or a related disorder, personality disorder, Tourette's disorder, or psychosis not otherwise specified. * Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as the primary diagnosis. * Known or suspected intelligence quotient (IQ) \< 70, suicidality, pregnancy, or substance or alcohol abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy and Safety of SPN-810 on the Frequency of Impulsive Aggression (IA) Measured by the Impulsive Aggression Diary | Daily measure from Visit 2 (Week -2) to Visit 6 (Week 5) for a total of 7 weeks | The primary efficacy endpoint was percent change (PCHT) in the frequency (unweighted score) of IA behaviors per 7 days in the treatment (titration and maintenance) period relative to the Baseline period calculated over the number of days with non-missing IA diary data. PCHT was then calculated as 100 x (T - B)/B, where T and B are IA behavior frequencies per 7 days during the treatment period (from Day 2 through Visit 6, inclusive) and baseline period (Day ≤1), respectively. The IA behavior frequency per 7 days is defined as (SUM/DAY) x 7, where SUM is the total of the IA behaviors reported in the subject IA diary, and DAY is the number of days with a non-missing IA score in the subject IA diary during the specified study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated | Visit 4 (Week 1), Visit 5 (Week 2) and Visit 6 (Week 5), a total of 4 weeks | The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator at each visit on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse |
| Effect of SPN-810 on Impulsive Aggression Measured by Child Health Questionnaire Parent Form 28-item (CHQ-PF28) | Baseline Visit 3 (Day 1) and Visit 6 (Week 5). Total duration of the study was 5 weeks. | The CHQ-PF28 is a short generic measure of health status and health-related quality of life. The 28 items have 4, 5, or 6 response options, divided over 8 multi-item scales (physical functioning, general behavior, mental health, self-esteem, general health perceptions, parental impact: emotional, parental impact: time, and family activities) and 5 single item concepts (role functioning: emotional/behavior, role functioning: physical, bodily pain, family cohesion, and change in health). In addition, the individual scale scores will be aggregated to derive 2 summary component scores: the physical functioning and psychosocial health summary scores. The range on subscales and the overall scale is 0-100 (0 = worst possible health state; 100 = best possible health state). Data represent the change from Baseline (Visit 3) to one time point, Visit 6 (Week 5). |
| Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Baseline Visit 3 (Day 1) and Visit 6 (Week 5). Total duration of the study was 5 weeks. | The PSI-4-SF is a 36-item self-report measure of parenting stress. Three subscales Parental Distress (PD), Parent-Child Dysfunctional Interaction (P-CDI), and Difficult Child (DC) consist of 12 items each. Parent chooses one of the 5 responses against each item. The 5 responses are: Strongly Agree (SA), Agree (A), Not Sure (NS), Disagree (D), and Strongly Disagree (SD) to indicate the degree to which they agree with each statement. The PD subscale raw score ranges from 12-60, P-CDI and DC each subscale raw score ranges from 16-56. The total stress raw score is the sum of the three subscales (PD+P-CDI+ DC) with a minimum score of 44 and a maximum score of 172. The total stress score is then converted into the percentile score. Parents with a 91st percentile or higher are experiencing clinically significant levels of stress. Data represents the mean change in percentile score from Baseline (Visit 3) and one time point, Visit 6 (Week 5). |
| Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) | Baseline/Visit 3 (Day 1), Visit 4 (Week 1), Visit 5 (Week 2), and Visit 6 (Week 5). The total duration of the study was 5 weeks. | The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors CGI-S was evaluated by the Investigator at each visit on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 3/Day 1) and three time points: Visit 4 (Week 1); Visit 5 (Week 2) and Visit 6 (Week 5). |
| Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Baseline Visit 3 (Day 1) and Visit 6 (Week 5). Total duration of the study was 5 weeks. | The Swanson, Nolan, Pelham Rating Scale-Revised (SNAP-IV) includes 18 ADHD and 8 oppositional defiant disorder (ODD) symptoms. The symptoms are scored on a 4-point scale, not at all=0, just a little=1, Quite a bit= 2, very much=3. The ratings from the SNAP-IV scale are grouped into the following 4 subscales: ADHD Inattention (items #1-9), ADHD Hyperactivity/Impulsivity (items#10-18), ODD (items# 19-26), and ADHD-combined (first two scales combined, items #1-18). Each observed subscale score is the average rating of the items scores for the subscale where scores range from 0-3; the higher is the score, worsen is the outcome. Data represent the change of the observed scores between Baseline (Visit 3) and the end of the study, Visit 6 (Week 5). |
| Effect of SPN-810 on Impulsive Aggression Measured by the Percentage of Responders | Daily measure from Visit 2 (Week -2) to Visit 6 (Week 5) for a total of 7 weeks | A Responder was defined as a subject with at least a 30% or 50% reduction in the frequency of IA behaviors per 7 days in the Treatment (Titration and Maintenance) period relative to the Baseline period per the IA Diary. Data represent the percentage of subjects with 30% and 50% reduction in IA behaviors from Baseline to end of treatment period. |
| Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated | Visit 4 (Week 1), Visit 5 (Week 2) and Visit 6 (Week 5), a total of 4 weeks | The CGI scale was developed to provide a brief, stand-alone assessment of the clinician's view of a subjects' global functioning prior to and after administration of a study medication. The scale was also rated by the Caregiver to assess the improvement of IA behaviors. . CGI-I was evaluated by the Caregiver at each visit on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Subjects treated with a Placebo | 92 |
| Low Dose SPN-810 (18 mg) Subjects treated with low dose of SPN-810 | 55 |
| High Dose SPN-810 (36 mg) Subjects treated with high dose of SPN-810 | 140 |
| Total | 287 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 12 |
| Overall Study | Lost to Follow-up | 3 | 1 | 3 |
| Overall Study | Other, Multiple categories | 1 | 1 | 1 |
| Overall Study | Physician Decision | 0 | 1 | 0 |
| Overall Study | Protocol Violation | 0 | 0 | 1 |
| Overall Study | Withdrawal By Parent/Guardian | 5 | 6 | 9 |
| Overall Study | Withdrawal by Subject | 0 | 2 | 3 |
Baseline characteristics
| Characteristic | Placebo | Low Dose SPN-810 (18 mg) | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|---|
| Age, Continuous | 9.3 years STANDARD_DEVIATION 1.66 | 9.0 years STANDARD_DEVIATION 1.9 | 9.0 years STANDARD_DEVIATION 1.87 | 9.1 years STANDARD_DEVIATION 1.81 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 18 Participants | 9 Participants | 24 Participants | 51 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 74 Participants | 45 Participants | 115 Participants | 234 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Asian | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Black or African American | 32 Participants | 22 Participants | 44 Participants | 98 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Other | 2 Participants | 3 Participants | 4 Participants | 9 Participants |
| Race/Ethnicity, Customized White | 56 Participants | 30 Participants | 91 Participants | 177 Participants |
| Retrospective-Modified Overt Aggression Scale (R-MOAS) | 63.91 units on a scale STANDARD_DEVIATION 33.43 | 66.38 units on a scale STANDARD_DEVIATION 27.894 | 67.34 units on a scale STANDARD_DEVIATION 31.949 | 66.06 units on a scale STANDARD_DEVIATION 31.637 |
| Sex: Female, Male Female | 20 Participants | 10 Participants | 26 Participants | 56 Participants |
| Sex: Female, Male Male | 72 Participants | 45 Participants | 114 Participants | 231 Participants |
| Vitiello Aggression Scale | -3.32 units on a scale STANDARD_DEVIATION 1.089 | -3.20 units on a scale STANDARD_DEVIATION 1.129 | -3.48 units on a scale STANDARD_DEVIATION 1.153 | -3.37 units on a scale STANDARD_DEVIATION 1.13 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 94 | 0 / 56 | 0 / 142 |
| other Total, other adverse events | 13 / 94 | 10 / 56 | 23 / 142 |
| serious Total, serious adverse events | 1 / 94 | 0 / 56 | 4 / 142 |
Outcome results
Primary
Efficacy and Safety of SPN-810 on the Frequency of Impulsive Aggression (IA) Measured by the Impulsive Aggression Diary
The primary efficacy endpoint was percent change (PCHT) in the frequency (unweighted score) of IA behaviors per 7 days in the treatment (titration and maintenance) period relative to the Baseline period calculated over the number of days with non-missing IA diary data. PCHT was then calculated as 100 x (T - B)/B, where T and B are IA behavior frequencies per 7 days during the treatment period (from Day 2 through Visit 6, inclusive) and baseline period (Day ≤1), respectively. The IA behavior frequency per 7 days is defined as (SUM/DAY) x 7, where SUM is the total of the IA behaviors reported in the subject IA diary, and DAY is the number of days with a non-missing IA score in the subject IA diary during the specified study period.
Time frame: Daily measure from Visit 2 (Week -2) to Visit 6 (Week 5) for a total of 7 weeks
Population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry. Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Efficacy and Safety of SPN-810 on the Frequency of Impulsive Aggression (IA) Measured by the Impulsive Aggression Diary | -54.12 Percent Change of IA behaviors |
| High Dose SPN-810 (36 mg) | Efficacy and Safety of SPN-810 on the Frequency of Impulsive Aggression (IA) Measured by the Impulsive Aggression Diary | -51.64 Percent Change of IA behaviors |
p-value: 0.938395% CI: [-8.96, 7.84]Wilcoxon (Mann-Whitney)
Secondary
Effect of SPN-810 on Impulsive Aggression Measured by Child Health Questionnaire Parent Form 28-item (CHQ-PF28)
The CHQ-PF28 is a short generic measure of health status and health-related quality of life. The 28 items have 4, 5, or 6 response options, divided over 8 multi-item scales (physical functioning, general behavior, mental health, self-esteem, general health perceptions, parental impact: emotional, parental impact: time, and family activities) and 5 single item concepts (role functioning: emotional/behavior, role functioning: physical, bodily pain, family cohesion, and change in health). In addition, the individual scale scores will be aggregated to derive 2 summary component scores: the physical functioning and psychosocial health summary scores. The range on subscales and the overall scale is 0-100 (0 = worst possible health state; 100 = best possible health state). Data represent the change from Baseline (Visit 3) to one time point, Visit 6 (Week 5).
Time frame: Baseline Visit 3 (Day 1) and Visit 6 (Week 5). Total duration of the study was 5 weeks.
Population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry. Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Child Health Questionnaire Parent Form 28-item (CHQ-PF28) | Physical Functioning Summary Score At Visit 6 | 7.98 score on a scale | Standard Deviation 11.461 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Child Health Questionnaire Parent Form 28-item (CHQ-PF28) | Psychosocial Health Summary Score At Visit 6 | 0.11 score on a scale | Standard Deviation 6.15 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Child Health Questionnaire Parent Form 28-item (CHQ-PF28) | Physical Functioning Summary Score At Visit 6 | 10.86 score on a scale | Standard Deviation 12.12 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Child Health Questionnaire Parent Form 28-item (CHQ-PF28) | Psychosocial Health Summary Score At Visit 6 | -2.29 score on a scale | Standard Deviation 9.282 |
Comparison: This analysis pertains to the Physical Functioning Summary Score at Visit 6.p-value: 0.340995% CI: [-1.64, 4.72]ANCOVA
Comparison: This analysis pertains to the Psychosocial Health Summary Score at Visit 6.p-value: 0.021595% CI: [-4.08, -0.33]ANCOVA
Secondary
Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated
The CGI scale was developed to provide a brief, stand-alone assessment of the clinician's view of a subjects' global functioning prior to and after administration of a study medication. The scale was also rated by the Caregiver to assess the improvement of IA behaviors. . CGI-I was evaluated by the Caregiver at each visit on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse
Time frame: Visit 4 (Week 1), Visit 5 (Week 2) and Visit 6 (Week 5), a total of 4 weeks
Population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry. Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated | Visit 6 | 2.7 score on a scale | Standard Deviation 1.26 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated | Visit 4 | 3.1 score on a scale | Standard Deviation 0.95 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated | Visit 5 | 2.9 score on a scale | Standard Deviation 1.14 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated | Visit 4 | 3.1 score on a scale | Standard Deviation 1.02 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated | Visit 5 | 2.7 score on a scale | Standard Deviation 0.94 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Caregiver Rated | Visit 6 | 2.5 score on a scale | Standard Deviation 1.12 |
Comparison: This analysis pertains to Visit 4p-value: 0.617195% CI: [-0.33, 0.2]Mixed Models Analysis
Comparison: This analysis pertains to Visit 5p-value: 0.061795% CI: [-0.55, 0.01]Mixed Models Analysis
Comparison: This analysis pertains to Visit 6p-value: 0.441995% CI: [-0.47, 0.21]Mixed Models Analysis
Secondary
Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated
The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator at each visit on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse
Time frame: Visit 4 (Week 1), Visit 5 (Week 2) and Visit 6 (Week 5), a total of 4 weeks
Population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry. Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated | Visit 4 | 3.4 score on a scale | Standard Deviation 0.72 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated | Visit 5 | 3.0 score on a scale | Standard Deviation 0.97 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated | Visit 6 | 2.8 score on a scale | Standard Deviation 1.13 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated | Visit 6 | 2.5 score on a scale | Standard Deviation 1.04 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated | Visit 4 | 3.3 score on a scale | Standard Deviation 0.9 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression-Improvement (CGI-I) Scale Investigator Rated | Visit 5 | 2.7 score on a scale | Standard Deviation 0.97 |
Comparison: This analysis pertains to Visit 4p-value: 0.088195% CI: [-0.41, 0.03]Mixed Models Analysis
Comparison: This analysis pertains to Visit 5p-value: 0.052295% CI: [-0.53, 0]Mixed Models Analysis
Comparison: This analysis pertains to Visit 6p-value: 0.176695% CI: [-0.52, 0.1]Mixed Models Analysis
Secondary
Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S)
The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors CGI-S was evaluated by the Investigator at each visit on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 3/Day 1) and three time points: Visit 4 (Week 1); Visit 5 (Week 2) and Visit 6 (Week 5).
Time frame: Baseline/Visit 3 (Day 1), Visit 4 (Week 1), Visit 5 (Week 2), and Visit 6 (Week 5). The total duration of the study was 5 weeks.
Population: Intent-to-Treat (ITT) Population: The ITT population included subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry.~Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) | Visit 4 | -0.27 score on a scale | Standard Deviation 0.518 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) | Visit 5 | -0.67 score on a scale | Standard Deviation 0.773 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) | Visit 6 | -0.93 score on a scale | Standard Deviation 0.997 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) | Visit 4 | -0.45 score on a scale | Standard Deviation 0.776 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) | Visit 5 | -0.96 score on a scale | Standard Deviation 1.068 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) | Visit 6 | -1.06 score on a scale | Standard Deviation 1.089 |
Comparison: This analysis pertains to Visit 4p-value: 0.097995% CI: [-0.33, 0.03]Mixed Models Analysis
Comparison: This analysis pertains to Visit 5p-value: 0.050295% CI: [-0.5, 0]Mixed Models Analysis
Comparison: This analysis pertains to Visit 6p-value: 0.476995% CI: [-0.38, 0.18]Mixed Models Analysis
Secondary
Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF)
The PSI-4-SF is a 36-item self-report measure of parenting stress. Three subscales Parental Distress (PD), Parent-Child Dysfunctional Interaction (P-CDI), and Difficult Child (DC) consist of 12 items each. Parent chooses one of the 5 responses against each item. The 5 responses are: Strongly Agree (SA), Agree (A), Not Sure (NS), Disagree (D), and Strongly Disagree (SD) to indicate the degree to which they agree with each statement. The PD subscale raw score ranges from 12-60, P-CDI and DC each subscale raw score ranges from 16-56. The total stress raw score is the sum of the three subscales (PD+P-CDI+ DC) with a minimum score of 44 and a maximum score of 172. The total stress score is then converted into the percentile score. Parents with a 91st percentile or higher are experiencing clinically significant levels of stress. Data represents the mean change in percentile score from Baseline (Visit 3) and one time point, Visit 6 (Week 5).
Time frame: Baseline Visit 3 (Day 1) and Visit 6 (Week 5). Total duration of the study was 5 weeks.
Population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry. Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Total Score at Visit 6 | -5.29 score on a scale | Standard Deviation 12.83 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Parental Distress Domain at Visit 6 | -1.02 score on a scale | Standard Deviation 5.486 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Parent-Child Dysfunctional Interaction Domain at Visit 6 | -2.13 score on a scale | Standard Deviation 5.593 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Difficult Child Domain at Visit 6 | -2.14 score on a scale | Standard Deviation 5.898 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Difficult Child Domain at Visit 6 | -3.94 score on a scale | Standard Deviation 6.406 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Total Score at Visit 6 | -7.38 score on a scale | Standard Deviation 15.757 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Parent-Child Dysfunctional Interaction Domain at Visit 6 | -2.42 score on a scale | Standard Deviation 6.663 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) | Parental Distress Domain at Visit 6 | -1.05 score on a scale | Standard Deviation 6.313 |
Comparison: This analysis pertains to the Total Score at Visit 6.p-value: 0.597795% CI: [-5, 2.89]ANCOVA
Comparison: This analysis pertains to the Parental Distress Domain score at Visit 6.p-value: 0.804995% CI: [-1.39, 1.79]ANCOVA
Comparison: This analysis pertains to the Parent-Child Dysfunctional Interaction score at Visit 6.p-value: 0.891195% CI: [-1.47, 1.69]ANCOVA
Comparison: This analysis pertains to the Difficult Child Domain score Visit 6.p-value: 0.142695% CI: [-2.93, 0.42]ANCOVA
Secondary
Effect of SPN-810 on Impulsive Aggression Measured by the Percentage of Responders
A Responder was defined as a subject with at least a 30% or 50% reduction in the frequency of IA behaviors per 7 days in the Treatment (Titration and Maintenance) period relative to the Baseline period per the IA Diary. Data represent the percentage of subjects with 30% and 50% reduction in IA behaviors from Baseline to end of treatment period.
Time frame: Daily measure from Visit 2 (Week -2) to Visit 6 (Week 5) for a total of 7 weeks
Population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry. Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Percentage of Responders | ≥ 30% Responder | 73.9 percentage of subjects |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Percentage of Responders | ≥ 50% Responder | 54.3 percentage of subjects |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Percentage of Responders | ≥ 30% Responder | 75.0 percentage of subjects |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Percentage of Responders | ≥ 50% Responder | 51.4 percentage of subjects |
Comparison: This analysis pertains to ≥ 30% Responders.p-value: 0.852595% CI: [0.58, 1.93]Regression, Logistic
Comparison: This analysis pertains to ≥ 50% Responders.p-value: 0.663595% CI: [0.52, 1.51]Regression, Logistic
Secondary
Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale
The Swanson, Nolan, Pelham Rating Scale-Revised (SNAP-IV) includes 18 ADHD and 8 oppositional defiant disorder (ODD) symptoms. The symptoms are scored on a 4-point scale, not at all=0, just a little=1, Quite a bit= 2, very much=3. The ratings from the SNAP-IV scale are grouped into the following 4 subscales: ADHD Inattention (items #1-9), ADHD Hyperactivity/Impulsivity (items#10-18), ODD (items# 19-26), and ADHD-combined (first two scales combined, items #1-18). Each observed subscale score is the average rating of the items scores for the subscale where scores range from 0-3; the higher is the score, worsen is the outcome. Data represent the change of the observed scores between Baseline (Visit 3) and the end of the study, Visit 6 (Week 5).
Time frame: Baseline Visit 3 (Day 1) and Visit 6 (Week 5). Total duration of the study was 5 weeks.
Population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry. Based on the results of the 810P301 interim analysis, enrollment in the 18 mg of SPN-810 group was halted and subjects planned to receive the 18 mg dose in Stage 2 were randomly assigned to 36 mg of SPN-810 or placebo in a 2:1 ratio.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Inattention subscale | -0.33 score on a scale | Standard Deviation 0.539 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Hyperactivity/Impulsivity subscale | -0.33 score on a scale | Standard Deviation 0.59 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Oppositional Defiant Disorder subscale | -0.50 score on a scale | Standard Deviation 0.685 |
| Placebo | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Combined subscale | -0.33 score on a scale | Standard Deviation 0.501 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Combined subscale | -0.48 score on a scale | Standard Deviation 0.576 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Inattention subscale | -0.46 score on a scale | Standard Deviation 0.593 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Oppositional Defiant Disorder subscale | -0.60 score on a scale | Standard Deviation 0.732 |
| High Dose SPN-810 (36 mg) | Effect of SPN-810 on Impulsive Aggression Measured by the Swanson, Nolan, Pelham Rating Scale- Revised (SNAP-IV) Rating Scale | Hyperactivity/Impulsivity subscale | -0.50 score on a scale | Standard Deviation 0.681 |
Comparison: This analysis pertains to the Inattention subscale at Visit 6.p-value: 0.041695% CI: [-0.32, -0.01]ANCOVA
Comparison: This analysis pertains to Hyperactivity/Impulsivity subscale at Visit 6p-value: 0.092195% CI: [-0.33, 0.02]ANCOVA
Comparison: This analysis pertains to the Oppositional Defiant Disorder subscale at Visit 6p-value: 0.44895% CI: [-0.26, 0.11]ANCOVA
Comparison: This analysis pertains to the Combined Scale score at Visit 6p-value: 0.045795% CI: [-0.31, 0]ANCOVA